RE SOURCES

2 0 1 5 A N N U A L R E P O R T

UNDERS TANDING p.11

EXPERTISE IN SKIN HEALTH

S O CIE T Y p.14
OSTEOARTHRITIS: A CHALLENGE FOR MOBILITY

REP ORT ING p.26

BEHIND THE SCENES
IN ÉPERNON

S A G A p.30
Corporate Social
Responsibility:
Expanscience
introduces its “Better
Living Program”
 PRESERVE
THE BEAUTY
OF YOUR SKIN
with complete safety
for your baby
100%
*

COMPAT I B LE
WITH BREASTFEEDING
SAFE FOR
M OT H E R A N D BA B Y

STRETCH MARKS
* All Mustela® Maternity formulas have been evaluated to be suitable for breastfeeding.

SKIN COMFORT
FIRMING

BREASTFEEDING

CLINICALLY-PROVEN EFFICACY

MUSTELA,
®
THE SKINCARE EXPERT FOR BABIES AND MOTHERS-TO-BE FOR OVER 60 YEARS.
DIRECTOR OF PUBLICATIONS
Jean-Paul Berthomé

EDITORIAL DIRECTOR
Sébastien Sillon

EDITOR-IN-CHIEF
Emmanuelle Dumas

EDITORIAL MANAGER
Nolwenn Sassier-Le Goff

DESIGN, CREATION,

EDITORIAL
PRODUCTION AND PRINTING
Aristophane

This annual report is published

by Laboratoires Expanscience.

PHOTO©
Getty Images
Fotolia
Expanscience photo library
2015:
A PIVOTAL
Thomas Deron

YEAR

By printing this annual report

on FSC and European
Ecolabel approved offset
paper, Expanscience
is helping to protect
the environment.
This document has been printed
by Ateliers Réunis, an
Imprimvert-certified printer.
Laboratoires Expanscience’s
contribution to sustainable
development has been
recognized as exemplary by
the AFAQ 26000 assessment.
Laboratoires Expanscience
has been a signatory
of the United Nations Global
Compact since 2004.
Laboratoires Expanscience
is a member of the UEBT
for protecting biodiversity
and complying with fair
trade regulations.
Cover Over the life of a company, some years have
© Getty Images
an especially decisive impact. At Laboratoires
Expanscience, 2015 was undoubtedly one
of those years. It’s been decisive for the success
of our products worldwide, for the production
records set by our manufacturing site, and above
all for the milestones we have reached,
the transformations we have successfully navigated
and the ambitions we have set for ourselves.
In 2015, for the first time, our international sales
exceeded our sales in France. Moreover, in 2015
we adopted a new business model in France
for Piasclédine 300, our drug for the treatment
of osteoarthritis. And in 2015 we drafted a five-year
plan of commitments with regard to Corporate
Social Responsibility, with the aim of pledging
new commitments between now and 2020.

The environmental All of these events are described in this fourth

management system that
Laboratoires Expanscience issue of Re Sources and make 2015 a pivotal year and
has developed for its R&D a collective human accomplishment.
and production activities
is ISO 14001-certified. These events are the result of strategic decisions
but also, first and foremost, the outgrowth of our
Since 2009, Laboratoires employees’ commitment to innovate in order
Expanscience has been
a signatory of the Charter to protect the health of our patients and consumers.
for Responsible Communications You can read what those employees have to say
from the French Advertisers
Association.
throughout this report, and you’ll quickly
understand why we have chosen to feature
their comments prominently!

Enjoy your reading!

The editorial team

 THE DAILY
DIAPER CARE
THAT CHANGES
EVERYTHING

1 2 3
PREVENTS RELIEVES REPAIRS
IRRITATION AND REDNESS

HIGH TOLER ANCE

0 % FRPREAGRSERAVATI
NCE
VE

OUR COMMITMENTS

98 INGREDIENTS
OF NATURAL ORIGIN
PARABEN - PHTHALATE
PHENOXYETHANO L
DESIGNED TO MINIMIZE
ENVIRONMENTAL IMPACT

MUSTELA ® , IT ALL STARTS WITH SKIN

 2015 ANNUAL REPORT E X PA NS C I E N C E 03

06
BENCHMARKS

11
Key figures
for 2015

UNDERSTANDING
Expertise
in skin health
08
HIGHLIGHTS
One year,
10 new developments

14
SOCIETY
Osteoarthritis:
a challenge for mobility

21
FEATURE
At the heart
of Laboratoires
Expanscience

INTERVIEW
Jean-Paul Berthomé
CEO
30
SAGA
04 Corporate social
responsibility:
REPORTING Expanscience
IR&D and production: introduces its “Better
behind the scenes Living Program”
in Épernon

26 34
HERE & THERE
A stronger
presence on
5 continents

SELECTED
ITEMS
Focus on
Expanscience
39
products SPONSORSHIP
A commitment
17 without borders
INTERVIEW

JEAN-PAUL
BERTHOMÉ
/
Laboratoires
Expanscience
CEO

HOW DO YOU REFLECT
ON 2015?
— The past year has been one in
which Expanscience demonstrated
its ability to adapt and pursue further
international growth. In order to meet
the challenge of Piasclédine 300, our drug
for the treatment of osteoarthritis, being
removed from the list of reimbursable
products in France, we adopted a new
business model, called OTX*, and have
succeeded in cementing our leadership
in pharmacies. Thanks to our energetic
distributors and the opening of new
subsidiaries - five in three years, notably
in Canada and Russia in 2015 - we passed
a critical milestone: for the first time in
our history, more than half of our turnover
came from outside France.
WHAT ASSESSMENT WOULD
YOU GIVE FOR EACH BUSINESS?
— In a challenging environment, we
have managed to expand our rheumatology
business, thanks to our overall turnover
from the portfolio and double-digit
growth abroad. With regard to our dermo-
cosmetics business, the revitalization of
our Mustela Bébé and Mustela Maternity
product lines has borne fruit, and Mustela’s
market share has increased in every
country, with a strong contribution from
our subsidiaries in Turkey, Belgium, Brazil
and France. Cosmetic active ingredients
also posted solid growth, thanks to the
launch of two active ingredients and our
efforts to capture new customers. Lastly,
the introduction of our Finhair Gé drug for
androgenic alopecia, and continued strong
sales of Effizinc, used to treat mild acne,
have boosted growth in dermatology.
IN 2010 EXPANSCIENCE ADOPTED A
NUMBER OF COMMITMENTS FOR 2015
WITH REGARD TO CORPORATE SOCIAL
RESPONSIBILITY (CSR). WHAT HAVE
BEEN THE RESULTS?
— I’m proud of the path we have
taken. Thanks to the energetic efforts
of the entire workforce, we have fulfilled
our commitments. Our CSR policy is an
increasingly integral part of the company,
and truly sets us apart in the eyes of
our target markets. It has won external
recognition in the form of 12 different
awards the company has received since
2012. Insofar as Expanscience and its
ecosystem are confronted with new
challenges (international expansion,
2015 ANNUAL REPORT
environmental and social concerns,
changing community attitudes toward
businesses, etc.), we have defined a
new road map for the next five years.
We’re calling this road map our “Better
Living Program,” and it contains our
commitments for 2020, all aimed at taking
better care of each of our communities,
including patients, consumers and
employees.
“ THE EXPANSCIENCE
OF THE FUTURE IS
A COMPANY WILLING
TO ADAPT, WITH
ETHICS, RESPECT AND
A RESPONSIVE ATTITUDE.
ALONG WITH ITS
PRODUCTS, IT OFFERS
AN ARRAY OF SERVICES
TO PATIENTS AND
CUSTOMERS THROUGHOUT
THE WORLD. ”
DURING THIS PAST YEAR YOU LED
AN INITIATIVE REGARDING YOUR
COMPANY’S IDENTITY AND CULTURE.
WHAT WAS YOUR OBJECTIVE?
—  During Expanscience’s current
growth phase, we saw a need to look
once again at the powerful and unifying
characteristics that bind our workforce
together, and the ways our employees
strive for innovation each day to preserve
the health of our patients and consumers.
Our aim was not merely to promote
unity and a sense of belonging among
our employees, but also to make us
more attractive to the candidates we
hire in the future, notably overseas.
Those considerations prompted us to
adopt a campaign to voice our conviction
that, as an employer: “Each one’s
potential makes everyone’s success.”
E X PA NS C I E N C E 05
WHAT ARE YOUR AMBITIONS
FOR 2016?
— We have objectives for advancing
and capturing growth in each of our
markets. First, we’re aiming for double-
digit growth for our Mustela brand in
the international market. This will be
driven by expanded market share in Asia,
a launch in the South African market,
our continued positioning as a Premium
brand in response to strong demand
worldwide, and our ongoing campaign
to roll out our new Mustela Maternity
product line. In rheumatology, too, the
international market will be instrumental
in driving growth, with the introduction of
Piasclédine 300 in Brazil. We also intend
to continue our progress in France in the
market for arthritis and osteoporosis by
strengthening our OTX model regarding
Piasclédine 300 – which test laboratory
was successful - and by introducing a
first-line treatment for osteoporosis
in menopausal women. Growth in our
cosmetic active ingredients business will
be led by a portfolio enhanced with new,
natural-origin active ingredients that
offer sensory appeal. Lastly, innovation
remains our priority: we’ll be maintaining
our EV.E.I.L.S** research program in
the fields of infant and pregnant women
skin, which in 2016 will continue to power
our expertise in skin health and our future
innovations.
WHAT DO YOU THINK EXPANSCIENCE
WILL LOOK LIKE IN 2020?
— It will look like a company that
acquired the resources to change and
adapt, and that goes beyond its products
to become something even more valuable
for patients and consumers. It will also
be a more international company, with
75% of its turnover generated outside
of France.
* A model based on over-the-counter sales
of Piasclédine 300 in connection with a medical
prescription
** Evaluation of Early Infant Life: the Skin
 
 06 BENCHMARKS

BEN CH MAR KS

K EY FIGURES
FOR 2015

€272.3 M IN TURNOVER

TURNOVER BY ACTIVITY:

58.9%
DERMO-COSMETICS
36.5 %
RHEUMATOLOGY

3.1 %
0.1 % DERMATOLOGY
INDUSTRY

1.4 %
COSMETIC ACTIVE INGREDIENTS
 2015 ANNUAL REPORT E X PA NS C I E N C E 07

85
DISTRIBUTING COUNTRIES

977EMPLOYEES

14
SUBSIDIARIES: AUSTRALIA, BELGIUM, BRAZIL,
CANADA, FRANCE, ITALY, MEXICO, POLAND,
PORTUGAL, RUSSIA, SPAIN, SWITZERLAND,
TURKEY, UNITED STATES

66
MILLION PRODUCTS
MANUFACTURED

843
PATENTS REGISTERED
WORLDWIDE

TURNOVER
BY GEOGRAPHICAL AREA

INTERNATIONAL FRANCE

51.3 % 48.7 %
08 HIGHLIGHTS
HIGHLIGHTS
O1
FOR FEELING
GOOD DURING
PREGNANCY
The new Mustela Maternity
line is designed to preserve
the skin’s beauty while ensuring
the baby’s safety, with seven
expert treatments specially
formulated to address the various
ways skin can change during
pregnancy. Guaranteed safe
for mother and child, clinically
proven to be effective, enjoyable
to use and made with ingredients
of natural origin whenever
possible, this new line of Mustela
products bears all the hallmarks
of the Mustela name.
ONE YEAR,
10 NEW
DEVELOPMENTS
O2
A NEW
DIGITAL
SHOWCASE
The expanscience.com website
has been completely redesigned
to more closely reflect
the company’s identity.
Contemporary, user-friendly
and intuitive, the new site
immediately envelops visitors
in the world of Expanscience,
from its know-how and services
in the fields of osteoarthritis
and skin health to its expertise
in innovation, research and
development, along with an
introduction to the company’s
products and its CSR policy.
As a true showcase for
Expanscience, it can be viewed
on any medium (computer,
tablet, smartphone).
O3
OSTEOARTHRITIS:
STRONGER
MARKET
DOMINANCE
At a time when slow-acting anti-
rheumatic drugs are no longer
reimbursable in France, Piasclédine 300
has managed to cement its leadership
status in pharmacies and among
healthcare professionals through an
emphasis on medical prescriptions.
Internationally, the drug has logged
double-digit growth in turnover.
O4
WORKING
ALONGSIDE
RESEARCHERS
As part of the Research on Osteo
Arthritis Diseases (ROAD) project and in
partnership with the Arthritis Foundation,
Laboratoires Expanscience are joining
forces with seven basic research units at
France’s Institute of Health and Medical
Research (INSERM) and National Center
for Scientific Research (CNRS). The goal
of the three-year program is to identify
new biomarkers for use in developing
innovative therapeutic strategies in the
treatment of osteoarthritis.

O5
CSR:
EXPANSCIENCE
HONORED
ONCE AGAIN
Expanscience was awarded
the top prize for its Corporate
Social Responsibility policy in
the “Governance, Ethics and
Responsible Management” category
of the first-ever 2015 CSR Awards,
hosted by Les Entreprises du
Médicament (LEEM), a trade
organization for the French
pharmaceutical industry.
The independent jury specifically
praised the comprehensive nature
of the company’s policy, in which
every employee has a role to play;
its deployment of an action plan
through a network of internal
liaisons; and the way the policy was
developed in cooperation
with company stakeholders.
O6
INTERNATIONAL
SALES: A DECISIVE
MILESTONE
For the first time in the history
of Laboratoires Expanscience,
and thanks to the strong
performance of the Mustela
brands and Piasclédine 300 on
every continent, turnover from
international sales surpassed that
of sales in France, which also
rose. This brings the company one
step closer to an objective that
Expanscience has set for 2020:
to obtain 75% of its turnover
from international markets.
2015 ANNUAL REPORT
O7
THE APP FOR
NEW MOTHERS
AND MOTHERS-
TO-BE
Mustela has created “Mustela & me”
an innovative support program
to ensure mothers have
a fulfilling pregnancy. This free app,
available in five languages, offers
daily tips and advice before, during
and after pregnancy.
It was elected “Best Sport, Health
and Wellness” app at France’s 2015
App Awards six months after
its launch.
O8
MUSTELA
MOVES INTO
CANADA
AND RUSSIA
To accelerate Mustela’s
international growth,
Expanscience opened two
new subsidiaries in Canada
and Russia - high-potential
markets where the dermo-
cosmetics brand was previously
distributed by partners. Five new
subsidiaries have been created
in the span of three years.
E X PA NS C I E N C E 09
09
EXPANSCIENCE AT
THE VANCOUVER
CONGRESS
At the 23rd World Congress of
Dermatology, held in Vancouver,
Expanscience presented the
results of 10 years of research
into the skin of newborns and
children to more than 100
opinion-leaders in the field
of dermatology from around
the world. The WCD is a major
event on the calendar of the
international dermatology
community.
10
TWO NEW
COSMETIC
ACTIVE
INGREDIENTS
Capitalizing on its expertise
in plant extraction and the
know-how of its research
teams, Expanscience expanded
its offerings for the cosmetics
industry with two innovative and
eco-designed active ingredients.
Pixalia, responsibly sourced
from Burkina Faso, acts on oily,
acne-prone skin in women
and teenagers. Made from
maca, a plant cultivated in Peru,
Macaline marks Expanscience’s
entry into the segment
of active ingredients for the body,
thanks to its threefold slimming,
firming and draining action.
 MUSTELA
CARE THAT IS NATURALLY SAFE AND
EFFECTIVE FOR YOUR SKIN

DID YOU KNOW...?

In light of the specific needs
of its target customers
and its strong commitment WE HAVE OPTED
to Corporate Social FOR “NATURALNESS” AS
Responsibility (CSR),
Expanscience has established A WAY TO PRESERVE DELICATE
its own natural products charter. SKIN MORE EFFECTIVELY.
Transparent and available to
the public at www.expanscience.com, WE SELECT THE BEST
the charter serves as a detailed INGREDIENTS OF NATURAL
specification for the Expanscience
personnel responsible ORIGIN IN ORDER TO PROVIDE
for formulations and procurement. SAFE, EFFECTIVE PRODUCTS
THAT ARE A PLEASURE
TO USE AND FRIENDLY
TO BOTH PEOPLE
AND THE ENVIRONMENT.

A NATURAL OIL
FOR PREVENTING
STRETCH MARKS QUANTIFIED NATURAL ORIGIN

Developed in collaboration with

healthcare professionals, including
Mustela has always looked pediatricians and dermatologists,
to the plant world to source the products in the Mustela Bébé
the main active ingredients and Mustela Maternity lines contain
that make up its products. an average of 92% and 86% ingredients
Made from 99% ingredients of natural origin respectively.
of natural origin*, Mustela
Maternity Stretch Marks
Prevention Oil is exemplary PRODUCTS THAT CONTAIN…
in its commitment to
naturalness. Its formula Mustela products have three types
combines five vegetable oils: of ingredients:
avocado, sunflower, baobab, — “natural” ingredients (water, oils,
pomegranate and musk rose. plant-based butters) that come
directly from nature;
Expanscience uses sustainable — ingredients of natural origin
sources of avocado (emulsifiers, gelling agents) that
and sunflower, with respect are obtained from nature but processed
for biodiversity as well as local using certain chemical procedures;
inhabitants. Its supply channels — selected synthetic ingredients
for plant-based raw materials (such as pH regulators), added solely
are subject to evaluation when no appropriate natural alternative
by the Union for Ethical is available.
BioTrade (UEBT) and include
precise traceability.
PRODUCTS THAT DO NOT CONTAIN...
In accordance with
To meet the needs of natural, sensitive

99 %
Expanscience’s eco-design
policy, Mustela Maternity baby skin, Mustela products are free
Stretch Marks Prevention of the following substances:
Oil is also friendly to Ammonium Lauryl Sulfate, Sodium
the environment through Lauryl Sulfate, p-Phenylenediamine
the end of its lifecycle, ingredients of natural origin and similar compounds,
thanks to a bottle that is in Mustela Maternity Stretch Phenoxyethanol, Paraben, Phthalates,
fully recyclable. Marks Prevention Oil BHA, Benzophenone, Ethylhexyl
Methoxycinnamate, Cyclotetrasiloxane,
Triclosan.
* The remaining 1% is attributable
to the need for an antioxidant
(tocopherol) to maintain the product’s
olfactory and general stability
over time. To find out more
View the Expanscience
natural products charter
at www.expanscience.com
 2015 ANNUAL REPORT
F I RST A ND FO REMOST
A MATTE R O F SC I EN C E
IRRITATION, DRYNESS, ACNE,
STRETCH MARKS... FROM BIRTH
TO ADULTHOOD, SKIN CAN
BE SEVERELY TESTED FOR
A VARIETY OF REASONS.
FACED WITH THESE ANNOYING
PROBLEMS, CONSUMERS
WANT PRODUCTS
FOR THEMSELVES AND
THEIR FAMILIES THAT ARE SAFE,
PLEASANT AND EFFECTIVE.
THE ABILITY TO FULFILL THAT
DESIRE REQUIRES A STRINGENT
AND THOROUGH RESEARCH
AND DEVELOPMENT PROCESS.
E X PA NS C I E N C E 11
UNDE RSTA NDING
SK I N H EA LTH
WHAT IF FEELING GOOD
ABOUT YOURSELF STARTED
WITH HEALTHY SKIN? 
The discomfort caused by irritated skin
is proof: babies cry because their bottom
is sore, expectant mothers worry they’ll lose
their youthful skin forever after childbirth;
teenagers are embarrassed by the acne
invading their face, etc.
To preserve the health of their own skin or that
of their child, today’s consumers are becoming
more and more demanding. They’re looking
for the most natural products available:
77% of mothers of infants up to age 6 months
prefer to purchase products that have natural
ingredients(1). They want products
for their baby that are safe and enjoyable
to use. For example, 61% of these mothers
pay close attention to the fragrance and scent
of the products they choose(1).
For themselves, they value safety and
effectiveness, especially to remedy stretch marks
and skin tightness resulting from pregnancy.
Laboratoires Expanscience address all of these
concerns through a rigorous and ambitious
strategy of innovation coupled with research
and development.
– (1) IFOP 2015, Quantitative U&A Questionnaire on Babies, France
77 %
OF MOTHERS OF INFANTS UP TO AGE
6 MONTHS PREFER TO PURCHASE
PRODUCTS WITH NATURAL INGREDIENTS.
12 U N D E R S TA N D I N G
UNDERSTANDING THE SKIN
OF PREGNANT WOMEN
In order to preserve skin health, you must
first have an exceptionally detailed knowledge
of the physiology of skin. That’s the aim of
a new chapter in Expanscience’s EV.E.I.L.S*
research program, which expanded in 2015
to include research on the skin of pregnant
women. These studies draw on substantial
human and technological resources
as well as partner research teams; coupled
with the recent discovery of the role played
by fibronectin, a protein, they’re providing
a better understanding of the essential steps
involved in the formation of stretch marks.
After ground-breaking research in which
cells from stretch-marked skin were
compared with cells from skin without
stretch marks, researchers were able to
evaluate the level of fibronectin production.
With the help of these new models,
they could then test the specific action
of different active ingredients. The results
were used to select the most effective active
ingredient: galactoarabinan (derived from
larch), chosen for its previously unknown
ability to stimulate production of fibronectin
and reduce the onset of stretch marks.
*EValuation of Early Infant Life : the Skin
X 1.5
IN 2015, EXPANSCIENCE
INCREASED ITS R&D
INVESTMENT IN MUSTELA
BY 150%.
SCIENTIFICALLY
PROVEN EFFICACY
With regard to infants,
the EV.E.I.L.S.* studies, which
have previously looked at normal
skin and the diaper area,
have now turned their attention
to other skin issues; in particular, the study
of normal skin is examining immature regulation
of the flow of water to the skin. In connection
with the study, Mustela Hydra Bébé Body Lotion
was clinically shown to be effective on key markers
for hydration. At the same time, researchers used
a new technology (triboacoustics) to define
and scientifically quantify skin softness, so as
to demonstrate the product’s positive effects.
Innovative strategies have
similarly been adopted
for developing two new active
ingredients intended for
the cosmetics industry
(see opposite). For the first,
Pixalia, which targets
acne-prone skin, IR&D was
able to demonstrate its effects during all four
phases of acne (inflammation, bacterial growth,
increase in sebum quantity, deterioration
of sebum quality), through in vitro testing
followed by clinical tests on volunteers.
For the second, Macaline, a new active ingredient
for the body, researchers turned to new
investigation techniques that proved its efficacy
on cellulite (even embedded cellulite), drainage
and skin firmness.
 2015 ANNUAL REPORT
MEETING THE CHALLENGE
OF NATURALNESS
To respond to international consumer demand
for products that are as natural as possible,
Innovation, Research & Development (IR&D)
has also focused its efforts on applying
Expanscience’s natural products charter, which
arose out of its Corporate Social Responsibility
policy. For all new product development,
researchers follow strict specifications regarding
natural products (see page 10). With its focus
on naturalness as a strategic asset in positioning
its dermo-cosmetics brands, Expanscience will
be expanding its communications to consumers
and healthcare professionals on the theme
of natural products in 2016.
THE MUSTELA PRODUCT LINE STANDS
OUT FOR ITS ETHICS, ITS SCIENCE,
ITS INNOVATION AND ITS SUSTAINABILITY,
ALL CONSISTENT WITH EXPANSCIENCE’S
CORPORATE SOCIAL RESPONSIBILITY POLICY.
DERMATOLOGICAL
EFFICACY
AND NATURALNESS
Intended for use in cleaning and caring
for acne‑prone skin in teenagers and adults,
the Boréade line of products from Noviderm
contains, on average, 90% ingredients of
natural origin, and Boréade products are 100%
eco-designed. Their formulations include
quinoa peptides, a patented active ingredient
with soothing properties. Quinoa peptides
were developed in 2011 by researchers at
Expanscience IR&D after their anti-inflammatory
properties were revealed in numerous studies
and discoveries regarding their use for acne.
E X PA NS C I E N C E 13
EACH EXPECTANT MOTHER
IS ALSO A WOMAN
The relaunch of Mustela Maternity has provided
an opportunity to redefine the territory for the
product line, which is intended for new and
expectant mothers. In addition to a new name that
is more emotional and less technical than “Mustela
9 months,” as well as more communicative product
names, the packaging has been changed to convey
more femininity and glamour, highlighting the
beauty of  a pregnant woman. The line clearly
addresses a need among women who take care
of themselves and want to preserve the beauty
of their skin without harming their child.
TWO INNOVATIVE NEW
COSMETIC ACTIVE
INGREDIENTS
With the release of Pixalia and Macaline in 2015,
expanding a portfolio that already includes some
twenty cosmetic active ingredients, Expanscience
is on track to meet its goal of introducing two new
active ingredients each year. Pixalia, which made
its debut at the In-Cosmetics trade show, is unique
in its ability to treat acne in both teenagers and
adult women. Sporting eco-designed packaging,
Pixalia is made from cleome gynandra, a plant
grown in Burkina Faso. With its threefold slimming,
firming and draining action, Macaline signals
Expanscience’s emergence in the market for active
ingredients for the body that go beyond treatment
for cellulite. Also marketed in eco-designed
packaging, Macaline has a formulation
based on maca, a plant already used in another
active ingredient (Skinergium®) and sourced
from an eco-friendly supply chain in Peru.
OUR AQUALICIA ACTIVE INGREDIENT
RECEIVED THE GREEN INGREDIENT
AWARD GOLD MEDAL AT IN‑COSMETICS
2015, IN HONOR OF ITS ECO-DESIGN
AND ACTIVE PROPERTIES.

OSTEOARTHRITIS
A COMPREHENSIVE
TO ENHANCING
WHEN OSTEOARTHRITIS STRIKES
THE CARTILAGE IN THE HIP OR KNEE,
THE ACCOMPANYING PAIN CAN
QUICKLY BECOME DISABLING.
THE RESULTING RISK OF ISOLATION
AND SELF-EXCLUSION MAKES
OSTEOARTHRITIS THE ELEVENTH
BIGGEST SOURCE OF DISABILITY
WORLDWIDE, ALL DISABILITIES
COMBINED(1). TO ENSURE
THAT PATIENTS CAN MAINTAIN
THEIR MOBILITY, EXPANSCIENCE
HAS BEEN PROMOTING A HOLISTIC
APPROACH TO TREATING
OSTEOARTHRITIS FOR MORE
THAN 20 YEARS.
- (1) The Lancet, 2012; vol. 380, no. 9859
SOC I E T Y
APPROACH
MOBIL ITY
ADVOCATING A HOLISTIC
FORM OF TREATMENT
Although there is still no cure for osteoarthritis,
its effects can be mitigated and its progress
slowed to improve the quality of life
for patients and prevent the need for surgery or
prostheses. The international recommendations
on this topic, such as those of the Osteoarthritis
Research Society International (OARSI), are clear:
osteoarthritis requires comprehensive,
coordinated treatment, both pharmacological
and non-pharmacological, that enlists the help
of physicians, pharmacists, physical therapists
and patients themselves (lifestyle, nutrition,
physical exercise, etc.).
GIVEN RISING RATES
OF OBESITY AND AGING
POPULATIONS IN DEVELOPING
COUNTRIES, OSTEOARTHRITIS
HAS EMERGED AS A GLOBAL
DISEASE.
 2015 ANNUAL REPORT E X PA NS C I E N C E 15

DIGITAL TECHNOLOGY
FOR HOLISTIC
TREATMENT
As patients become increasingly connected
to the digital world, Expanscience is opting
for digital technology to provide enhanced support.

THE RISK OF A site devoted to Piasclédine 300

was introduced online in late 2015
DEMEDICALIZATION to give patients the information
IN FRANCE they need regarding their disease
and its treatment. The site will
www.piascledine.fr become available in different
The decision by France’s health authorities languages during 2016.
to stop the reimbursement of so-called
slow-acting anti-rheumatic drugs (SAARDs)
A customized support service
will have an inevitable effect on patient for osteoarthritis patients, featuring
comfort, especially for patients on a limited enhanced ergonomics and content
budget. If they are not reimbursed for their as of 2015 as well as a new
treatment, many of the five million patients community forum, will help more
than 10,000 registered patients
diagnosed with osteoarthritis(2) may choose
share information and advice.
to forgo future visits to the physician. www.arthrocoach.com A Spanish version of the site
A study conducted for Latin America will be introduced
With 20 years of in June 2015(3) indicates in late 2016.
that patients are
experience in the
unwilling to treat their With more than 40,000 visits each
comprehensive treatment osteoarthritis on their month, arthrolink.com is the
of osteoarthritis, own and are in critical preeminent website on
osteoarthritis for patients and
Expanscience is stepping need of advice and
healthcare professionals alike.
support from their In 2015 the site was expanded
up its commitment
medical practitioner. www.arthrolink.com to include a list of supplemental
to physicians and Over time, this health insurance policies that
pharmacists to ensure “demedicalization” could cover slow-acting anti-rheumatic
drugs (SAARDs).
that patient quality of life lead to increased rates
of surgery, as can be
is not adversely affected
observed in countries
by this decision where medical treatment
to demedicalize is less advanced.
treatment for - (2) Out of 10 million French people
affected; source: Livre blanc de l’arthrose
the disease. 2015.
- (3) WR Conseil study report for EXPANSCIENCE
TEAMING
Laboratoires Expanscience on the
impact of discontinuing reimbursement
for Piasclédine 300 (meetings with
groups of osteoarthritis patients
in Paris, Lille and Lyon). UP FOR RESEARCH
INTO OSTEOARTHRITIS

N
  °1
FROM MARCH TO DECEMBER 2015,
In December 2015, Expanscience was selected
to participate in and help fund the three-year ROAD
Project (Research on Osteo Arthritis Diseases),
a research program led by France’s Arthritis
PIASCLÉDINE 300 CEMENTED ITS STATUS
Foundation on chronic inflammatory rheumatic
AS THE MARKET LEADER BOTH IN UNITS
SOLD IN PHARMACIES AND IN diseases. Bringing together France’s seven largest
THE NUMBER OF PRESCRIPTIONS centers for basic research into osteoarthritis
WRITTEN BY GENERAL PRACTITIONERS (including laboratories at INSERM and CNRS),
AND RHEUMATOLOGISTS. the ROAD Project is designed to advance
Source: GERS Sell-Out, CSD-CAM. our knowledge of osteoarthritis and cell aging.
16 SOCIETY

EXPANDED OUTREACH
TO PATIENTS
Expanscience launched a major initiative to make
Piasclédine 300 more visible in pharmacies
and to enhance its packaging, its price
(now capped so as not to penalize patients)
and its presentation (now in packs of 30 capsules
rather than 15, more convenient for those
with chronic illness). In addition, a communications
campaign (web, print media, radio) was launched
targeting the general public to encourage medical
treatment for osteoarthritis. With the same goal
in mind, the company held a press conference
in September 2015. All of these actions have borne
fruit: at a time of declining sales overall, Piasclédine
300 has cemented its leadership in the market
for osteoarthritis treatment (see page 15).
A STRATEGIC DECISION
TO EMBRACE A NEW BUSINESS
A COMPLETE PORTFOLIO
MODEL FOR PIASCLÉDINE 300
FOR RHEUMATOLOGY
When Piasclédine 300 was delisted for
In 2016, Expanscience will be consolidating
reimbursement in France in March 2015,
this new business model with help from
Expanscience was quick to foresee the impact
the other products in its portfolio: Hyalgan
and responded by adopting and deploying
(injectable hyaluronic acid), Takadol (analgesic),
a new business model, dubbed OTX, based
Fixical (vitamin-calcium supplement)
on over-the-counter sales of the drug in
and Nabucox (non‑steroidal anti-inflammatory).
connection with a medical prescription.
And as a guarantee of medium-term growth,
The entire company mobilized to carry out this
Expanscience will be introducing a new drug
major change. To reduce the risk that treatment
in 2016 for first-line treatment of osteoporosis
for osteoarthritis would be removed from a
in menopausal women.
medical context - a trend that would harm
patient quality of life - the campaign focused
on highlighting the critical support provided
by healthcare professionals. Medical sales
representatives increased their efforts among
general practitioners and rheumatologists, and
also educated pharmacy personnel to give them
a better understanding of the disease.
OSTEOARTHRITIS IS FRANCE’S LEADING
CAUSE OF DISABILITY AMONG THOSE
AGED 40 OR OLDER AND THE SECOND
LEADING CAUSE OF VISITS TO GENERAL
PRACTITIONERS.
 MUS T EL A BÉBÉ MUS T EL A S UN CARE

1 2 3 VITAMIN BARRIER CREME VERY HIGH PROTECTION SUN SPRAY

MUS T ELAA
MUSTEL MUS
M U STT EL
ELAA
M AT ERNI
MATE TY
RNITÉ S T EL ATOPIIA
ST E L ATOP A

CRÉME PRÉVENTION VERGETURES BAUME RELIPIDANT STELATOPIA

STRETCH MARKS PREVENTION CREAM LIPID-REPLENISHING BALM
 MUS T EL A SUN CARE MUS T EL A BÉBÉ

Preser ve their skin Effica cy, safet y, ple asure

for the future. of use from bir th on.

VERY HIGH PROTECTION SUN LOTION • VERY HIGH MASSAGE OIL • PHYSIOBÉBÉ • CLEANSING MILK • HYDRA BÉBÉ
PROTECTION SUN SPRAY 200 ML • VERY HIGH PROTECTION BODY LOTION  •  DERMO CLEANSER  •  HYDRA BÉBÉ FACIAL
SUN SPRAY 300 ML • AFTER SUN SPRAY CREAM  •  1 2 3 VITAMIN BARRIER CREME

MUS T EL A S T EL ATOP IA MUS T EL A MAT ERNI T Y

A new life Preser ve the be aut y

for e czema-prone skin. of your skin with complet e
safet y for your baby.

BUST FIRMING SERUM  •  BODY FIRMING GEL

LIPID-REPLENISHING BALM  •  EMOLLIENT CREAM LIGHT LEGS GEL  •  SOOTHING MOISTURIZING BALM
CREAM CLEANSER  •  MILKY BATH OIL STRETCH MARKS PREVENTION OIL  •  STRETCH MARKS PREVENTION
CREAM  •  STRETCH MARKS RECOVERY SERUM
 As exp er ts in the t re a tme nt
of oste o ar thritis for more
than 20 y e ars, Labora toires
E xp anscie nc e provide
c omprehe nsi ve c are for
oste o ar thritis of the kne e
and hip and offer t re a tme nt
tha t is prove n effe c ti ve,
along with ser vic es
for da y -to -da y sup por t.

www.arthrocoach.com

www.arthrolink.com

www.piascledine.fr

RHE UM ATOLO GY

PIASCLÉDINE 300 MG
dr ug

Franc e’s to p - selling

slow - a c ting sy mptoma tic
anti- rheuma tic dr ug.
Source: GERS Sell-Out CMA 2015.

DERMATOLO GY DEN TAL CARE

PROCUTA Gé 20MG HYALUGEL GEL

drug me dic al devic e
 RHE UM ATOLO GY

An exhaustive, comprehensive line of produc ts

for the tre atment of osteoar thritis, calcium deficiency and pain.

dr ugs
FLEXEA 625 MG  •  FIXICAL VITAMIN D3, 1000 MG/800 UI  •  TAKADOL 100 MG
NABUCOX 1 G  •  PIASCLÉDINE 300 MG  •  HYALGAN 20 MG/2 ML

SOLD ONLY IN FR ANCE E XCEP T PIA SCLÉDINE 300 AND FLE XE A.

DEN TAL CARE DER MATOLO GY

A complete produc t line A wide se le c tion of therapeutic

for mouth pain, now expanded tre atments for mild to severe a cne
to include infant teething care in both adolescents and adults,
with Hyaluge l 1 st teeth. and a dr ug for the tre atment
of androgenetic alope cia in men.

me dic al devic es dr ugs

HYALUGEL SPRAY  •  HYALUGEL ADO  DOXYLIS Gé 100 MG • EFFIZINC 15 MG
HYALUGEL 1ST TEETH  •  HYALUGEL GEL  •  HYALUGEL MOUTHWASH PROCUTA 40 MG • FINHAIR Gé 1 MG

SOLD ONLY IN FR ANCE. SOLD ONLY IN FR ANCE.

 F E AT UR E

At the heart
of Laboratoires
Expanscience:
each one’s potential
makes everyone’s
success.

Beyond each individual’s talents and expertise, Expanscience employees share the same vision
and are bound together by the strong, unifying traits that constitute the company’s DNA: initiative,
creativity, performance, openness, solidarity, innovation, pride in belonging and responsibility. Each
day, these characteristics, defined in the wake of a 2015 workshop on Laboratoires Expanscience’s
identity, are concretely reflected in the way we work and in projects and actions dedicated to our
collective success, all to fulfill our common mission: protecting your health through innovation.

#PERFORMANCE #PRIDE #INNOVATION #RESPONSIBILITY

#CREATIVITY #INITIATIVE #SOLIDARITY #OPENNESS

22 F E AT U R E
# INNOVATION
LABORATOIRES EXPANSCIENCE
WERE ESTABLISHED IN 1950
FROM A COLLABORATION
BETWEEN A MANUFACTURER,
PAUL BERTHOME, AND
A PHARMACIST, CLAUDE
GUILLON. THEIR TALENT WAS
TO CREATE A MINDSET AND
AN ENTREPRENEURIAL SPIRIT
THAT CONTINUE TO DRIVE
THE WORKFORCE EVEN TODAY.
MORE THAN SIXTY YEARS LATER,
EXPANSCIENCE BRINGS NEARLY
1,000 EMPLOYEES TOGETHER
BEHIND A SHARED CULTURE
AND IDENTITY.
# SOL IDARITY
ANTICIPATING THE NEEDS OF THE FUTURE
With 87 patents registered in France and
843 patent applications filed worldwide,
Expanscience has innovation in its blood!
Since 1950, Expanscience’s Research
& Development Center has been developing
original formulations and new active principles
for maintaining health. To meet that objective,
the company also creates innovative services
for lending support to consumers, patients
and healthcare professionals.
“In order to introduce new dermo-cosmetics products
and respond to the needs of consumers, we need to adopt
new technology and conduct innovative research, both as a
preliminary step, to take our knowledge of the skin even further,
and during the actual development phase, through the use
of new in vitro methods, and the clinical phase.”
FRANCK MENU
Cosmetic Innovation
and Development Manager
STRENGTHENING THE TIES
THAT BIND US
Commitment to the community is an integral part
of Expanscience, reflected in the sponsorship
activities led by the Fondation Mustela for more
than three decades and the company’s proactive
Corporate Social Responsibility policy, established
in 2004. Consistent with that commitment, since
2015 Expanscience has been offering its workforce
the opportunity to support projects by two
humanitarian organizations, Care France and
Action Enfance, through micro-donations,
in a show of employer/employee solidarity.
Employees who wish to participate can
lend support to either organization through
a monthly micro-donation deducted from
their salary that is matched by Expanscience.
Fondation Mouvement
pour les Villages d’Enfants
 2015 ANNUAL REPORT E X PA NS C I E N C E 23

# OPENNESS
ADAPTING TO NEW HORIZONS
In order to innovate, improve our procedures
or capture new markets, Expanscience
employees need to explore new paths.
This open-minded attitude played a critical
role during the initial months of Expanscience’s
new Russian subsidiary, tasked with raising
the Mustela brand’s profile in the various
regions of the country.

“We visited numerous regional events and conventions

for pediatricians to talk about the discoveries from
our EV.E.I.L.S research program on infant skin from
birth, and we explained exactly how and why we give
priority to ingredients of natural origin in our product
formulations. At the same time, in a country where
mothers are very careful about the products they
choose for their babies, we visited numerous ‘schools
for mothers’ where we could meet with them one on
one. The reception we received from both healthcare
professionals and mothers suggests that there’s
a very bright future for sales of Mustela in Russia.”

ARINA BAYBURTYAN
General Manager Russia
# RESPONSIBIL ITY
# CREATIVITY
ENSURING THAT EVERYONE
CAN SPUR PROGRESS
Creative companies are more agile and innovative.
That’s why Expanscience is developing a culture
of innovation that fosters creativity among its
employees. With that goal in mind, in 2007
the company created Graine d’ID, a system
of participatory innovation that lets employees
propose ideas on their own or in response
to specific concerns. Two hundred ideas
were submitted during 2015 in a variety of areas
(international development, improvements
in day-to-day procedures, production,
commercial development of innovations).
After being evaluated by special committees,
these ideas were subsequently implemented
within Expanscience and will help ensure
our success in the future!
TAKING ACTION ON BEHALF
OF SUSTAINABLE GROWTH
For more than a decade, Expanscience has been
developing an ambitious – and widely hailed –
policy of social and environmental responsibility
that not only generates value for the company’s
target audience but serves to differentiate
Expanscience brands (see page 30). Taking care
of young children and new and expectant mothers
also means protecting their environment, so
Mustela acts in every way possible to minimize
the environmental impact of its products at each
stage of their lifecycle.
“The eco-design we use for Mustela products, which encompasses
their entire lifecycle, addresses two of the primary expectations
among young mothers: naturalness and safety. As a laboratory,
we feel obligated to think about what will happen at the end
of each product’s life. So we take numerous concrete steps
to educate consumers about proper sorting procedures
in the bathroom. In my view, that’s an essential part of being
a responsible dermo-cosmetics brand, especially one focused
on a period of life that’s so important for the future.”
SYBILLE FOING
Mustela France
Marketing Director

# PE RFORMANCE
RESPONSIBLE, PRODUCTIVE GROWTH
For Expanscience, growth is inseparable
from the desire to provide consumers
and patients with effective, safe solutions
that help to improve both their health
and their quality of life. That approach,
which has guided the group’s international
expansion, can be seen in the treatment
for osteoarthritis, an increasingly prevalent
disease worldwide. In the nearly forty
countries where Piasclédine 300 is
distributed, our local workforce offers
comprehensive treatment options for
osteoarthritis patients and provides support
to healthcare professionals – as in Chile,
where the drug has consolidated its position
as the market’s top‑selling product.
“Chile is a booming market (thanks to economic growth and
high rates of osteoarthritis), but also a very competitive one.
That’s why our local sales partner has an extensive team of
medical sales representatives who promote Piasclédine 300
among a wide range of healthcare professionals (primarily
general practitioners, rheumatologists and orthopedic
surgeons). After six years on the market, our specialty is now
the leading product in its category. We work with our partner
to find and deploy new digital and marketing tools, to ensure
we’re constantly more knowledgeable about prescribers
and their needs.”
ROMAIN RENARD
Area Sales Manager –
Latin America
# PRIDE
LENDING MEANING TO ALL OUR ACTIONS
Over the years Expanscience has been honored
on numerous occasions for the ongoing efforts
of its employees, who make a daily commitment
to responsible economic growth, more virtuous
products and helpful support services
for its customers and healthcare professionals.
This recognition is a source of pride, credibility,
legitimacy and progress for a company that
has always been eager for transparency regarding
its offerings and its CSR policy. The past year
was especially fruitful in this regard. Expanscience
won awards for its CSR policy (LEEM(1) Award,
the Green Ingredient Award for its cosmetic active
ingredient Aqualicia, Responsible SME Award),
for its services on behalf of patients and
consumers (arthrocoach.com, “Mustela & me”),
and for its products (2015 Family Brand Award for
Mustela in the “Pregnant woman beauty products”
and “Beauty & care products for children” categories;
123 Vitamin Barrier Cream voted 2016 product
of the year).
(1) LEEM: Les Entreprises du Médicament, a trade organization for the French
pharmaceutical industry.
CONCRETE STEPS
TO IMPROVE WORKPLACE
QUALITY OF LIFE
Convinced of the strong link between
professional well-being and individual
and collective performance, Expanscience
maintains a workplace quality of life program
for its employees. In line with the corporate
social responsibility policy, the program
aims to improve workplace practices
through concrete actions and services:
AGREEMENT ON GENDER EQUALITY
AND PAY EQUITY
PROGRAMS TO PROMOTE
A WORK-LIFE BALANCE
PERFORMANCE CYCLE WITH THREE
EMPLOYEE/MANAGER INTERVIEWS EACH YEAR
HEALTH WEEK
DISABILITY ACTION PLAN
EMPLOYEE SATISFACTION ASSESSMENT
VIA INTERNAL SURVEY
AND MORE
 E X PA NS C I E N C E 25

THE EXPANSCIENCE
#PRIDE IDENTITY
AT THE HEART
OF ITS NEW
“EMPLOYER BRAND”

In October 2015, Expanscience unveiled

# INITIATIVE
EXPANDING THE POSSIBILITIES
For Expanscience, there’s more
to preserving health than offering safe
and effective products and treatments.
To demonstrate that conviction, the
company develops innovative services
that provide support to consumers,
patients and healthcare professionals –
services like arthrocoach.com,
a personalized digital coaching resource
for people suffering from osteoarthritis.
its new human resources communications
campaign. Designed to encourage employee
loyalty, create a cohesive workforce
and attract candidates for employment,
the campaign sums up the company’s
identity with an explicit tagline: each
one’s potential makes everyone’s success.
To illustrate that belief and demonstrate
the attention Expanscience gives to its men
and women, the campaign describes
the network of talents to which every
employee contributes and the strong,
unifying traits that bind the workforce
together: initiative, creativity, performance,
openness, solidarity, innovation, pride
in belonging and responsibility.

“Arthrocoach.com works in tandem with physicians

by serving as a companion that patients can use between visits
to the rheumatologist. The tool helps patients progress at their
own pace by coaching them on their physical activity
and nutrition. Its monitoring curves give them a clearer picture
of their progress and the improvements they still need to make.
Available for computer, tablet or smartphone, the tool was
developed in partnership with rheumatologists and experts
in physical and nutritional coaching. A Spanish version for Latin
America will be introduced in the near future.”

LAURENCE MARCHAL
Digital Manager
 2266 R E P O R TA
I NGGE

RE PORT ING

IR&D AND PRODUCTION

BEHIND
THE SCENES
IN ÉPERNON
RESPONDING TO TODAY’S CONSUMER
DEMAND AND ANTICIPATING THE DEMAND
OF THE FUTURE: THAT’S THE TWOFOLD
RESPONSIBILITY OF OUR SITE IN
ÉPERNON, HOME TO THE IR&D CENTER
AND PRODUCTION. HERE’S A LOOK AT
A KEY RESOURCE FOR EXPANSCIENCE’S
GROWTH, A SITE THAT BOASTS A WIDE
RANGE OF EXPERTISE AND CONSTANTLY
ADAPTS TO PROVIDE SUPPORT
FOR THE COMPANY’S STRATEGY.
 2015 ANNUAL REPORT E X PA NS C I E N C E 27

Challenge
met!
The Expanscience production site has
successfully kept pace with growing
demand in its international markets.
Production capacity for Piasclédine 300,
Expanscience’s flagship anti-rheumatic
drug, rose to a new high in 2015 of more
than 420 million capsules. Production in
dermo‑cosmetics climbed to record levels
as well, with 22 million Mustela bottles
produced in 2015. These accomplishments
are the result of employees mobilizing
behind the performance plan launched in 2014
(see page 29). The outlook for 2016 is just as
promising. For example, a new production
line for dermo-cosmetics that came online
at the start of the year will produce 10 million
additional Mustela products in tube format.
An intense year
for the IR&D center
What with the EV.E.I.L.S. studies on infant skin,
research into the skin of pregnant women,
multiple new Mustela products developed,
the launch of two new cosmetic active
ingredients, expanded scientific communication
and more, the IR&D center had an exceptionally
busy year in 2015. It also invested in the future.
In addition to hiring new employees, the center
acquired innovative new analytical technology
for generating more sensitive and specific
data. It lets researchers characterize in detail
the chemical structures that make up each
product (raw materials, active ingredients,
finished products) so as to provide an even
stronger guarantee of their quality and safety.

A key regional
player
Based in Épernon near Paris since 1957,

1 = 3
Expanscience is also notable for
the role it plays in local economic development.
An economic impact study conducted by
1 JOB AT EXPANSCIENCE an independent organization* offers proof: the
CREATES OR MAINTAINS Épernon site alone accounts for 11% of all jobs
3 ADDITIONAL JOBS in the pharmaceutical, cosmetics and chemical
IN THE FRENCH
sectors in the surrounding département of
ECONOMY
Eure-et-Loir. To uphold its regional role and
responsibilities, Expanscience maintains an
ongoing dialogue with its local stakeholders.
* Local Footprint methodology, Utopies.

€50 M
IN INDUSTRIAL
A NEW INSTALLATION
OFFERING A THREEFOLD BENEFIT
INVESTMENT In 2015 the Épernon site unveiled a new facility
OVER THE NEXT FIVE YEARS devoted to molecular distillation, a process used to
AT THE ÉPERNON SITE produce active ingredients of natural origin, including
the Avocado oil and Soybean oil Unsaponifiables*
used in the composition of Piasclédine 300 and the
cosmetic active ingredients derived from sunflower

66 M
UNITS PRODUCED IN 2015,
oil. This equipment will double the site’s production
capacity and drastically reduce its electricity use
and water consumption (the latter by more than
10,000 m3 annually), while slashing production costs.
INCLUDING 44 MILLION
* ASU
DERMO‑COSMETICS
UNITS AND 22 MILLION
PHARMACEUTICAL UNITS
28 REPORTING
01
02
01
COORDINATING AND MOBILIZING
TO ENSURE SUCCESS
“I oversee the production unit for active
principles of natural origin, such as those
used to produce our Piasclédine 300 drug.
I’m involved in multidisciplinary teams,
with members drawn from the support
functions, that manage and carry out
projects for improvement. In addition
to coordinating and monitoring activity
in a workshop that operates 24 hours
a day, 7 days a week, 315 days a year,
my job is to coordinate, mobilize and
empower our employees. That requires
a lot of listening, communication and
support to ensure we can successfully
tackle the numerous challenges we face.”
STÉPHANE GENÈVE /
CHEMICAL UNIT MANAGER
03
02
A POLICY
OF CONTINUOUS IMPROVEMENT
“On a day-to-day basis, I’m responsible
for checking the physical-chemical analytical
reports for the raw materials and the
pharmaceutical and cosmetics products that
enter and leave our manufacturing site.
One of the major projects in our Performance
Plan is to improve how the inspection laboratory
is organized. For my part, I’m working with
the Innovation Research & Development Center
to review some of our inspection techniques,
in order to make them faster and more accurate
or to bring them in line with new, more efficient
technology. Our goal is to see improvement
every day in the quality of the products
we provide to customers.”
SONIA WASIELEWSKI /
PHYSICO-CHEMISTRY TECHNICAL LEADER
- INDUSTRIAL QUALITY CONTROL
03
HIGH-RESOLUTION ANALYSES
“My colleagues and I develop analytical
methods covering the raw material up
to the finished product that are then
used by the quality control staff during
the production process. For that task,
we now have cutting-edge analytical
technology in the form of high-resolution
mass spectrometry, which will enhance our
analytical resources and expertise for all
types of products, including raw materials,
active ingredients and finished products.
Thanks to this new investment, we can
be even more effective and ensure even
greater quality and safety in the products
we bring to the market.”
NELLY LEGOUT /
ANALYTICAL DEVELOPMENT
PROJECT LEADER, INNOVATION,
RESEARCH & DEVELOPMENT CENTER
 2015 ANNUAL REPORT E X PA NS C I E N C E 29

04 04
AMERICAN-STYLE QUALITY

“Our Mustela Bébé 123 Vitamin Barrier Cream

is officially classified as a drug in the United
States. As a result, it needed to comply with
the American pharmaceutical guidelines
in order to be sold in the US market. That’s
what the US regulatory agency, the Food and
Drug Administration, came to verify as part
of an inspection at the Épernon site. That
inspection, which involved several different
teams at the site, offered an opportunity to
review our procedures and strengthen our
05 quality policy even further, by applying certain
pharmaceutical requirements to our cosmetics
products. I’m proud to have helped meet that
challenge as a Quality Products Executive.”

CATHERINE GOSSET /
QUALITY PRODUCTS EXECUTIVE,
INDUSTRIAL QUALITY

05
SHORTER PRODUCTION TIMES
“As an equipment operator on the cosmetic
bottles line for 16 years, I participated
in the Performance Plan project to see how
we could improve production times.
For six months, I worked alongside several

06
of my colleagues to observe and analyze
the various steps for changing bottle formats
on the line, the machine configurations,
the factors that contribute to breakdowns
and so on. We reported on the problems
we found and suggested improvements.
Once new standards and handling times had
been defined, we looked at how they would
actually work on the ground, to ensure they
were consistent and applicable for day‑to‑day
operations. Ultimately we made a lot of
progress, and I felt that this process was a
real acknowledgement of my experience.”

PATRICK BAUDÉ /
EQUIPMENT OPERATOR,
DERMO-COSMETICS PRODUCTION UNIT

06
EXTREMELY DEMANDING TESTS
“In order to comply with the formulation
specification for Mustela Maternity Stretch
Marks Prevention Oil – which calls for safety,
efficacy, pleasure in use, naturalness and
respect for people and the environment
– we tested quite a large number of
plant oils. After various stability tests and
toxicology studies, we selected five oils:
avocado, pomegranate, sunflower, musk
rose and baobab. We eventually succeeded
in developing an oil for preventing stretch
marks that is 99% of natural origin, that
doesn’t leave a greasy film and that offers
remarkable olfactory stability. I’m very
proud that it received a Victoires de
la Beauté consumer award in France.”

TEDDY DUPUIS /
FORMULATOR, INNOVATION,
RESEARCH & DEVELOPMENT CENTER
30 CSR SAGA

Corporate
Social
SAGA Responsibility:
A DECADE
OF ACTIONS TAKEN
AND COMMITMENTS MET

2O1O FOR MORE THAN 10 YEARS, EXPANSCIENCE

A SET OF CORE CSR HAS MAINTAINED A DEMANDING CORPORATE
COMMITMENTS FOR THE YEAR
2015 IS FORMALLY DEFINED SOCIAL RESPONSIBILITY POLICY TO IMPROVE
THE DAILY LIVES OF ITS PATIENTS AND CONSUMERS,

2O11 ENHANCE ITS VALUE TO SOCIETY AND REDUCE

EXPANSCIENCE BECOMES
A MEMBER OF THE UNION
FOR ETHICAL BIOTRADE (UEBT)
ITS IMPACT ON THE ENVIRONMENT. IN THE PAST
FIVE YEARS, THIS GOAL HAS BEEN FORMALLY LAID
OUT IN AMBITIOUS OBJECTIVES THAT THE COMPANY

2O12
ISO 14001 CERTIFICATION
OF THE ÉPERNON SITE
IS PROUD TO HAVE MET, THANKS TO A DIALOGUE
WITH ITS STAKEHOLDERS AND ITS EFFORTS TO
MOBILIZE NEARLY 1,000 EMPLOYEES WORLDWIDE.

2O13
EXPANSCIENCE BECOMES
THE FIRST PHARMACEUTICAL
AND DERMO-COSMETICS
LABORATORY WHOSE
CONTRIBUTION TO SUSTAINABLE
DEVELOPMENT IS RECOGNIZED
AS EXEMPLARY BY AFAQ 26000

2O14
EXPANSCIENCE CELEBRATES
10 YEARS OF MEMBERSHIP
IN THE UNITED NATIONS GLOBAL
COMPACT, THE STARTING POINT
FOR ITS COMMITMENT TO
A PROACTIVE CSR POLICY

2O15
CHALLENGE MET! EXPANSCIENCE
FULFILLS THE COMMITMENTS
SET IN 2010*
* Except for the targets
for lower energy consumption
and waste production
at the Épernon site

2O16
EXPANSCIENCE LAUNCHES
THE BETTER LIVING PROGRAM:
ITS PROGRAM OF COMMITMENTS
FOR 2020 TO HELP MAKE
LIFE BETTER IN ALL
OF ITS COMMUNITIES
 2015 ANNUAL REPORT
PRODUCTS THAT ARE
FRIENDLIER
TO THE ENVIRONMENT
RESPONSIBLE SUPPLY
LINES FOR PLANT
RAW MATERIALS
2015 objective: Expanscience will
have implemented a CSR action plan
for 100% of its plant supply chains
FULFILLED
In each of its 19 supply chains for the plant raw
materials that form the basis of the pharmaceutical
active ingredients and certain cosmetic active
ingredients used in its products, Expanscience
has established an action plan to ensure respect
for biodiversity and compliance with fair trade
principles. This initiative has been recognized
by the Union for Ethical BioTrade (UEBT)
since 2011. Expanscience’s procurement policy
won additional plaudits in 2015: Aqualicia,
an acacia-derived cosmetic active ingredient,
was honored with a Green Ingredient Award
for its composition and the sustainability of its
development process. In sourcing its acacia from
Burkina Faso, Expanscience offers economic
opportunities to a group of female harvesters
and responds to local concerns regarding
biodiversity protection and human development.
455
EMPLOYEES TRAINED
IN EXPANSCIENCE’S CSR
POLICY IN 2015 USING THE
CSR PASSPORT: A TRAINING
PROGRAM (INFORMATION,
COLLABORATIVE WORKSHOP,
GAMES AND MORE)
DESIGNED TO PROMOTE
A FULLER UNDERSTANDING
OF THE POLICY
12
AWARDS BESTOWED
ON EXPANSCIENCE’S
CSR POLICY
SINCE 2012
E X PA NS C I E N C E 31
2015 objective:
Establish an action plan to reduce
the environmental impact
of our principal drug
FULFILLED
Piasclédine 300, an Expanscience drug used to treat
osteoarthritis, was subjected to a lifecycle analysis
to identify its environmental impact. Since the drying
process used for avocado, the key ingredient in
Piasclédine 300, is the largest contributor to the
product’s environmental impact, Expanscience
defined an action plan with its partner avocado
producers. In Peru, for example, the plan helped
to reduce natural gas consumption by 18%**.
In Épernon, the Avocado oil and Soybean oil
Unsaponifiables used to create the drug are then
produced in a facility built to High Environmental
Quality (HEQ) standards. An effluent pretreatment
plant has been installed as well. Moreover, by
packaging Piasclédine 300 in packs of 30 capsules
rather than 15, the volume of paper and cardboard
used for the product has been reduced.
** Between 2010 and 2015, per 100 units produced
2015 objective: All new Mustela
and Noviderm dermo-cosmetics
products will be eco-designed in 2015
FULFILLED
“As of 2014, all new dermo-cosmetics products
are subjected to our evaluation tool dubbed EENOE
(from the French acronym for “Together Let’s
Eco‑Design Our Expanscience Products”). We use
the tool to gauge the effort that went into developing
a new dermo-cosmetics product, with a view
to reducing its environmental impact at each stage
of its lifecycle. This assessment is performed on
the basis of qualitative and/or quantitative data on
five factors: raw materials and formulation, primary
and secondary packaging, tertiary packaging,
industrial manufacture, use. To qualify as eco-
designed, a new product must outperform its
reference product by obtaining a higher score both
overall and on at least one of the five factors.
To give one example, all of the products in the Mustela
Bébé range relaunched in 2014 met that standard.”
Marie-Noëlle Joinville
Cosmetic Innovation and Eco-Design Manager
 36 SAGA RSE

EXPANDED SOCIAL
RESPONSIBILITY

2015 objective: introduce

an employee skills development
policy to promote professional
development and improve
the company’s performance

FULFILLED

ENVIRONMENTAL “Since 2010, our human resources policy

IMPACT REDUCED,
OUR RESOURCES PRESERVED
2015 objective: Reduce natural gas,
electricity and water consumption
and waste production at the Épernon
site (IR&D and production) by 20%
PARTIALLY FULFILLED
“Between 2010 and 2015, our water consumption per
100 units produced was cut by 22% and our natural
gas consumption by 25%, thanks to upgrades and
improvements (boiler insulation, burner replacement
and so on). We reduced electricity consumption by
16% by replacing compressors and optimizing lighting
and climate control in the production units. These
water and energy savings will increase in 2016 with
the new molecular distillation facility (see page 27).
Waste production, meanwhile, increased by 38.5%
over the period. Seventy percent of the waste
produced consists of the sludge generated when
tanks are washed; if this rinse water is excluded,
waste production fell by 19%.
The commissioning of a second pretreatment
plant in late 2016 will reduce our volumes
of waste to a very substantial degree.”
Didier Levêque, Site Director
2015 objective: Reduce
greenhouse-gas emissions by 20%
FULFILLED
has made professional development a priority.
Each employee now has three annual meetings
with his or her manager (annual interview, evaluation
interview, career development interview).
We’ve also established a monthly meeting with
all managers so they can talk to their teams about
the company’s direction and key projects. Moreover,
we’ve led some major initiatives regarding mobility
and qualifications. For example, medical sales
assistants have had the chance to acquire
the skills to become medical sales representatives,
while machine operators received 70 hours
of training to obtain a professional certificate
of qualification.”
Fanny Debbi, Human Resources Director
2015 objective: Complete
the Workplace Quality of Life program
FULFILLED
Numerous actions have been taken with regard
to workplace quality of life, including a campaign
to promote work/life balance, enhanced medical
coverage, a Health Week event held annually
since 2013 for employees in France and abroad,
and an employee satisfaction survey conducted
since 2012. This policy has yielded dividends:
in France, Expanscience was awarded the 2015
Victoire d’Or du Capital Humain award in the
pharmaceutical industry, given to companies
with the best HR policies.

Our efforts have been successful!

At equivalent production levels,
our greenhouse-gas emissions are 25%
lower than those of 2008***.
*** At equivalent production levels, excluding sourcing
of raw materials and subsidiaries’ distribution activities.

-20.5 %
OUR REDUCTION OF NATURAL
GAS AND ELECTRICITY
CONSUMPTION COMBINED
BETWEEN 2010 AND 2015
AT THE ÉPERNON SITE,
PER 100 UNITS PRODUCED
 2015 ANNUAL REPORT
Corporate
Social
Responsibility
What
new goals
for 2020?
INCREASINGLY GLOBAL OPERATIONS, CHANGING
BUSINESS STRATEGIES, NEW STAKEHOLDER EXPECTATIONS
FOR BUSINESSES, NEW ENVIRONMENTAL AND SOCIAL
CONCERNS... ON THE STRENGTH OF A CSR POLICY
DEFINED MORE THAN A DECADE AGO, EXPANSCIENCE
IS TARGETING NEW MILESTONES WITH ITS PROGRAM
OF COMMITMENTS FOR 2020. ITS GOAL: TO HELP
IMPROVE LIVES IN EACH OF ITS COMMUNITIES (PATIENTS,
CONSUMERS, EMPLOYEES) BETWEEN NOW AND 2020,
AS PART OF THE LABORATOIRES EXPANSCIENCE
“BETTER LIVING PROGRAM”.
E X PA NS C I E N C E 33
INNOVATE IN A RESPONSIBLE
AND COLLABORATIVE WAY
This new road map is designed to make corporate social
responsibility even more integral to the Expanscience organization,
so that the company becomes a greater contributor to society
and anticipates community needs more effectively. Building
on the commitments pledged for 2010-2015, the Better Living
Program contains new objectives drafted jointly by Expanscience
and its internal and external communities.
PROGRESS WITH OUR COMMUNITIES
Laboratoires Expanscience are also committed to expanding
their business responsibly, both in France and worldwide, by
consistently combining progress with ethics in developing their
innovations. Expanscience hopes to meet these challenges while
making progress alongside its communities.
TAKE CARE OF OUR CUSTOMERS
AND OF THEIR ENVIRONMENTS
As its way of caring for its customers and their environment,
Laboratoires Expanscience and their brands pledge to provide
products that are more responsible throughout their lifecycle,
and to creating solutions that enhance treatment and aid
prevention in the areas of skin health and osteoarthritis.
34 HERE & T HERE

H E RE & THE RE
A ST RONG E R
PRESENCE
ON 5
CONT INE NTS

IN 2015 EXPANSCIENCE
REACHED A SYMBOLIC
AND DECISIVE MILESTONE. Our performance of the past year
FOR THE FIRST TIME,
offers proof: Expanscience is on track
to meet its objective for 2020
ITS INTERNATIONAL of generating 75% of its turnover
TURNOVER EXCEEDED ITS from international markets.
TURNOVER IN FRANCE, The share of sales outside France has risen from
WHICH ALSO INCREASED. 44.9% in 2013 to 46.1% in 2014 and 51.3% in 2015.
The acceleration over the past year can be attributed
HERE’S A LOOK BACK
to the export success of Expanscience’s business lines
AT HOW VARIOUS and the performance of its subsidiaries.
PRODUCTS PERFORMED
The dermo-cosmetics business built on its past
IN THE PRINCIPAL achievements and captured new ground, thanks to
COUNTRIES WHERE the relaunch of Mustela Maternity, the success of
123 Vitamin Barrier Cream and the bestsellers in the
THEY ARE MARKETED.
Mustela Bébé line (Dermo-Cleansing, Hydra Bébé,
etc.). The rheumatology business logged an impressive
increase in sales volume for Piasclédine 300 outside
France (up 20%), on the strength of organic growth
and consolidation of the market share first captured
in 2014.
Lastly, the cosmetic active ingredients and dermatology
business lines (see page 38) saw turnover increase
by 15% and 5% respectively.

51.3 % 75 % 60 % 15 %

SHARE OF EXPANSCIENCE OF TURNOVER FROM SHARE OF MUSTELA GROWTH IN
TURNOVER INTERNATIONAL SALES. TURNOVER FROM PIASCLÉDINE 300
GENERATED OUTSIDE THAT’S THE GOAL INTERNATIONAL SALES BY VOLUME
FRANCE IN 2015 EXPANSCIENCE HAS SET SALES IN 2015 IN 2015
FOR 2020
UNDISPUTED
LEADERSHIP
POSITIONS
IN EUROPE
To cement Mustela’s position as
Europe’s top-selling pharmacy
brand, Expanscience opened a subsidiary in Russia
in June 2015. This country offers significant growth
potential in the market for dermo-cosmetics baby
products. Middle-class mothers in Russia are willing
to spend more on quality infant care products. In
its first months of operation, the new subsidiary
has been working on getting its products into retail
outlets and on the brand’s name recognition among
healthcare professionals. Initial results for 2016
suggest Expanscience is on track to fulfill its goal
of making Mustela Russia’s top-selling Premium
infant brand. Our subsidiary in Poland has captured
success by focusing on its launch of Mustela
Maternity in a market dominated by local brands.
The Turkish subsidiary, established in 2013, delivered
on the promise of that booming market by gaining
new market share.
Western Europe posted an impressive performance
as well, thanks to the especially warm reception
given to the new Mustela Maternity line and the
Mustela Bébé line, which has cemented its leadership
position (with market share of 50% to 70% in some
countries). Italy is a perfect example of this sales
momentum, with Mustela Bébé vaulting to the top
of the market in pharmacy sales. The Portuguese
and Spanish subsidiaries have likewise seen steady
growth, despite the economic crisis. In Belgium,
EUROPE
where Mustela Bébé has the highest market share
of any country in the world (73%), the subsidiary
changed its logistics partner so as to improve the
quality of service provided to customers in 2016.
In France, thanks in particular to 123 Vitamin Barrier
Cream, reintroduced in 2014, Mustela Bébé increased
its market share by two points, strengthening
its position as the market leader well ahead of its
nearest rival (all distribution channels combined).
Mustela Maternity, meanwhile, garnered an excellent
reception in pharmacies and logged substantial
growth in the stretch marks segment (with market
share up nine points). In 2016 Mustela plans to
consolidate its market position in care products
for infants, children, mothers and mothers-to-be.
The brand will be expanding its digital and media
promotions and increasing its visibility at points of
sale. In addition, it will be presenting Expanscience’s
R&D findings on atopic skin to healthcare professionals.
PIASCLÉDINE 300 During 2015 Piasclédine 300
posted strong results
in the six Central European countries where it is
marketed, particularly in Poland, the Czech Republic
and Slovakia. In Russia the product was buffeted by the
impact of regional geopolitics and the economic crisis.
Nonetheless, positive momentum had returned by the
end of the year, prompting hopes for a recovery in 2016.
France’s decision in March to discontinue reimbursement
for slow-acting symptomatic anti-rheumatic drugs
weighed on sales of Piasclédine 300. But with
Expanscience’s adoption of a new business model
for its drug (see page 16), Piasclédine 300 has
reasserted its market leadership, increasing its lead
over its nearest competitor and gaining market share.
36 HERE & T HERE

AME RICAS

STRONG MOMENTUM
IN NORTH AND
SOUTH AMERICA

PIASCLÉDINE 300 Given the strong potential

in Latin America,
Expanscience has hired a special regional sales
manager in Brazil, tasked with boosting sales of
Piasclédine 300 on the continent. The product
has performed impressively in its two major
markets, Chile (where it ranks first in market share)
and Argentina. In Mexico, 2015 ended with a strong
sales performance (a 10% increase in market
share), despite an exceptionally competitive market.
And in preparation for the launch of Piasclédine 300
in the Brazilian market in Spring 2016, Expanscience
has selected a partner to operate in the country,
which represents the biggest market for SAARDs*
in South America.
* Slow-Action Symptomatic Anti-Rheumatic Drugs The 2015 opening of a subsidiary in
Canada, a country ranked among the
top 10 worldwide in purchasing power, has already
produced results. Mustela reported 40% growth
in Canadian sales during 2015, thanks to a sharp
acceleration in the number of pharmacies stocking
Mustela products, plus targeted trade campaigns
that focused on the quality of the products.
The Mexican subsidiary, for its part, returned to a path
of growth in 2015 after reintegrating several support
functions that had previously been outsourced.
Its Brazilian counterpart, established in 2013, enjoyed
steady growth by expanding into Brazil’s southern states
and anticipates a promising year in 2016, thanks to the
late-2015 launch of 123 Vitamin Barrier Cream in the
world’s second largest market for the category. And
in the United States, Mustela has maintained its position
in the face of new rivals that have invested heavily in
the media and at retail outlets.
 2015 ANNUAL REPORT E X PA NS C I E N C E 37

AFRICA AND
THE MIDDLE EAST:
GROWTH DRIVERS
IN THE MAKING

PIASCLÉDINE 300 In September 2015,

Piasclédine 300 made
a successful debut in the South African market,
suggesting a positive outlook for 2016. In North
Africa, sales continued to improve in Morocco
– a long-standing market for Piasclédine – but
were hampered in Algeria by the government’s
decision to follow the path of its French
counterpart in discontinuing reimbursement
for anti-rheumatic drugs. The Middle East
posted a solid sales performance in the three
major countries managed by our Cairo-based
partner: Eg ypt, Saudi Arabia and Iran.

After tripling its turnover on the

African continent over the past four
OCEANIA years, Mustela continued to see strong growth
in 2015, notably in Algeria, Morocco and Ivory Coast.
In 2016 the brand will be targeting South Africa, the
only major African country where it has not been
available, in conjunction with a local partner. In
addition, to oversee growth in the dermo-cosmetics
business in the Middle East – a region that offers high
potential, given the number of births, the extensive
use of medical care and elevated purchasing power
– Expanscience has opened an office in Dubai.
OCEANIA:
HIGH AMBITIONS
IN AUSTRALIA
With 23.1 million inhabitants, more than 300,000
births annually and a growing economy for more
than 20 years, Australia offers strong potential for
Mustela. With that in mind, Expanscience established a
subsidiary in the country in 2014 to boost sales,
which had been handled by a distributor for the
previous decade. In 2015 the subsidiary continued to
anchor its standing in the market by making the brand AFRICA
more visible, with the aim of capturing 50% of the
Premium market for infant skin care in pharmacies
over the coming years. The year was also marked by
a first for the subsidiary: The science committee for
the Annual Scientific Meeting, a major dermatology
conference in Australia, invited Expanscience
to present the results of its EV.E.I.L.S. research
program on infant and child skin.
 SUSTAINED GROWTH
FOR COSMETIC ACTIVE
INGREDIENTS
Expanscience’s cosmetic active ingredients business,
which markets cosmetic active ingredients
and sensory ingredients in about fifteen countries,
tallied double-digit growth in 2015, notably thanks
AS I A to Aqualicia, a cosmetic active ingredient
for cell hydration that was introduced in 2014.
In addition to performing exceptionally well
in France, its primary market, the business
has expanded its sales in China, where Premium
active ingredients are in growing demand among
local firms seeking to move upmarket.

Soline, a moisturizing active ingredient with soothing

and lipid-replenishing properties, has had a banner
STRENGTHENING year in the United States thanks to the successful
launch of a flagship product for a prestigious
OUR STRATEGIC international brand. Finally, in partnership with
FOOTHOLD IN ASIA a local distributor, Expanscience has established
a presence in Turkey to serve as a launching pad
for the markets in the Middle East.
With turnover that has doubled in
just two years, Asia has emerged as
Mustela’s second biggest marketing region after
Europe. This record can be attributed to Mustela
Bébé’s exceptionally strong performance in China
in 2015, with turnover up 180%. Expanscience has
invested heavily in the brand over the past three
years to increase its penetration rates at points of
sale and capture this extremely promising market
(with 16 million births annually). The market has
been boosted by increased buying power among
a substantial segment of the population, which is
increasingly turning to Premium products. On the
Asian continent as a whole, the Mustela Bébé and
DERMATOLOGY:
Maternity product lines have likewise posted strong OUR ADDITIONAL
growth, especially in Hong Kong and Taiwan. SKIN EXPERTISE
PIASCLÉDINE 300 In Southeast Asia, where In France, home to Effizinc, Doxylis Gé and
Expanscience relies on Procuta Gé, Expanscience offers a wide range of oral
a local distributor to market Piasclédine 300, the treatments for mild to severe acne in adolescents
year ended with a 300% increase in sales in Malaysia, and adults. In 2014 we expanded our portfolio
the Philippines and Vietnam. To coincide with of dermatological drugs with Finhair Gé, formulated
Piasclédine 300’s 2014 launch in Vietnam, two to treat androgenic alopecia in men ages 18 to 41.
scientific symposiums highlighting Expanscience’s Thanks to vigorous sales of Finhair Gé coupled with
expertise in osteoarthritis were held with increased market share for Effizinc and Doxylis Gé,
rheumatologists and other members of Vietnam’s the business line as a whole logged a 5% increase
medical community. In South Korea, where in turnover by drawing on its close relationships
Piasclédine 300 is sold under the name Imotun, the with dermatologists.
drug consolidated its position as market leader among
the products in its class over the past several years.
SPONSORSHIP
A COMMIT MENT
WITHOUT BORDE RS
CHILD DEVELOPMENT,
FAMILIES, PARENTHOOD,
SUPPORT FOR SENIORS...
EXPANSCIENCE IS EXPANDING
ITS PHILANTHROPIC EFFORTS
IN WAYS THAT REFLECT ITS
CORE IDENTITY. BOTH
IN FRANCE AND WORLDWIDE,
ITS COMMITMENT TRANSLATES
INTO SUPPORT FOR RESEARCH
PROJECTS AND INITIATIVES LED
BY HEALTHCARE PROFESSIONALS
AND NON-GOVERNMENTAL
ORGANIZATIONS.
1982
CREATION OF THE FONDATION MUSTELA
120
AWARDS AND RESEARCH GRANTS
GIVEN BY THE FONDATION
MUSTELA SINCE 1982
IN THE FIELDS OF PSYCHOLOGY,
SOCIOLOGY, PSYCHIATRY
AND MAIEUTICS
A PARTNER
TO RESE ARCHERS
Each year the Fondation Mustela bestows awards and
research grants for initiatives likely to have practical
applications that improve the treatment options available to
professionals in the field of child care and child health.
In 2015 the foundation awarded two grants, one on how
children see health and another on parental bonds. The
foundation also announced two winners of its Maieutics
Prize in France for midwives. One prize was awarded to a
researcher examining the institution of the contemporary
family, while the second went to a study of fungicides and
their impact on child development.
The Maieutics Prize is also awarded in Belgium and, as of 2015,
in Poland, where the maiden winner was a research project
to improve perinatal health. In addition, the Research Action
Award, designed to support innovative initiatives for child
development within the family or institutional environment,
was given to a project studying ways to prevent conflicts
in mother-child relationships.
"From physiological to psychological, cognitive and
emotional development: childhood in all its aspects
has been at the heart of the projects funded by the
Fondation Mustela for more than 30 years. As it has grown
and developed, the Fondation Mustela has continued to
support healthcare professionals and kept faith with its
determination to tackle new questions and introduce new
ways of working. Getting older while remaining young at
heart – surely that’s the best way to grow up."
Chantal Larcade
Chief Representative of the Fondation Mustela

ACTIVELY WORKING
IN THE FIELD BOTH
IN FRANCE AND WORLDWIDE
The Fondation Mustela supports numerous initiatives targeted
to children and families and led by healthcare professionals or
select NGOs. In 2015, the foundation’s Social Pediatrics Prize
was awarded to Dr. Valentina Dell’Orto, a physician from the
Hôpital Antoine-Béclère in Clamart, France, for her project
to prevent feeding difficulties in premature newborns.
In Lebanon, the foundation renewed its support for ASMAE,
a child protection organization associated with the NGO
Soeur Emmanuelle. Always alert to international emergencies,
the Fondation Mustela also awarded an exceptional grant of
€40,000 to Enfance Nepal in the wake of the earthquake that
struck the country on April 28, 2015.
With a presence in 20 countries, the Fondation Mustela has
lent support to several Expanscience subsidiaries, including
those in Italy (to help fund villages for abandoned children),
Portugal (for the well-being of young patients from families
experiencing difficulties) and Turkey (for early education for
women to boost their career prospects). At the same time,
it has worked with supply chains for plant raw materials
to fund projects targeting local populations, in Burkina Faso
and elsewhere.
The past year also saw the foundation step up its prevention
outreach initiatives for the general public, including the
reissue of an informative brochure to enhance the status of
the midwifery profession and the creation of an interactive
game for children, available at its website, to help them learn
about bodily hygiene.
20
THE NUMBER OF COUNTRIES WHERE
PROJECTS HAVE RECEIVED SUPPORT
FROM THE FONDATION MUSTELA
A REVAMPED
WEBSITE
The Fondation Mustela’s website has been
completely redesigned to be more informative
for the general public. The site is available
in two versions, one for a general audience
and the other for healthcare professionals,
who can order information and prevention
packs at no charge or apply for
the foundation’s various grants and awards.
With just a few clicks, visitors can learn
about the foundation’s various activities or
view interactive media. Italian, Polish, Turkish,
Dutch and Portuguese versions of the site
are also available.
Visit us at www.fondationmustela.com
A HISTORY OF SUPPORT
FOR DERMATOLOGICAL
AND OSTEOARTHRITIS
RESEARCH
As it has each year since 1998, Laboratoires
Expanscience awarded two osteoarthritis
awards in 2015 for clinical and basic research,
totalling €3,820 each, along with an award
for dermatology research in the amount
of €5,000. These awards are presented
in partnership with the Société Française
de Rhumatologie and the Société Française
de Dermatologie respectively.
 Throughout
the world
FRANCE
10, avenue de l’Arche
92419 COURBEVOIE Cedex
•
AUSTRALIA
Suite 107-108
685 Burke Rd
Camberwell VIC 3124
•
BELGIQUE
SPHERE BUSINESS PARK
Z3 Doornveld 124 2C1
1731 ZELLIK
•
BRASIL
Rua Samuel Morse 74,
Conj. 162, Berrini
04576 060
SAO PAULO
•
CANADA
QC Montréal
2001 Boul. Robert Bourassa Suite 17069
MONTREAL – H3A 2A6
•
ESPAÑA
C/Marie Curie n°7
Edificio ß – 1a planta – oficina 1.6
28521 Rivas-Vaciamadrid, MADRID
•
ITALIA
Via Moncucco 20/22
20142 MILANO
•
MÉXICO
Amsterdam No 229, Piso 1– Col. Hipodromo
CP 06100 MEXICO, DF
•
POLSKA
UI. Żelazna 67/78
00-871 WARSZAWA
•
PORTUGAL
Avenida António Augusto de Aguiar Nº 21 – 4º Esq.
1050-012 LISBOA
•
SUISSE
Rue Jacques Grosselin, 8
CP 1035
1211 GENÈVE 26
•
TURKEY
Barbaros Mah. Kardelen Sok. No : 2
Palladium Tower Kat 18
34746 Atasehir, İSTANBUL
•
USA
60 East 56th Street, 6th Floor
New York, NEW YORK 10022
•
RUSSIA
Posledny Per., 11 b.1
107045, MOSCOW

www.expanscience.com